These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 21220972)

  • 1. The local efficacy of I-131 for F-18 FDG PET positive lesions in patients with recurrent or metastatic thyroid carcinomas.
    Yoshio K; Sato S; Okumura Y; Katsui K; Takemoto M; Suzuki E; Katayama N; Kaji M; Kanazawa S
    Clin Nucl Med; 2011 Feb; 36(2):113-7. PubMed ID: 21220972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
    Lee JW; Lee SM; Lee DH; Kim YJ
    J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.
    Rosenbaum-Krumme SJ; Görges R; Bockisch A; Binse I
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1373-80. PubMed ID: 22718304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
    Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
    J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of patient age on the iodine/FDG "flip-flop" phenomenon in lung metastasis from thyroid cancer.
    Isoda T; BaBa S; Maruoka Y; Kitamura Y; Tahara K; Sasaki M; Honda H
    Ann Nucl Med; 2016 Oct; 30(8):518-24. PubMed ID: 27380042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.
    Wang W; Larson SM; Tuttle RM; Kalaigian H; Kolbert K; Sonenberg M; Robbins RJ
    Thyroid; 2001 Dec; 11(12):1169-75. PubMed ID: 12186505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.
    De Luca S; Fonti R; Camera L; Salvatore B; Faggiano A; Ciarmiello A; Segreto S; Colao A; Salvatore M; Del Vecchio S
    Ann Nucl Med; 2016 Apr; 30(3):234-41. PubMed ID: 26753628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. F-18 FDG PET/CT in the management of thyroid cancer.
    Iagaru A; Kalinyak JE; McDougall IR
    Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression free survival related to
    Zhu X; Wu S; Yuan X; Wang H; Ma C
    Hell J Nucl Med; 2019; 22(2):123-130. PubMed ID: 31273354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data.
    Middendorp M; Selkinski I; Happel C; Kranert WT; Grünwald F
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):76-83. PubMed ID: 20168289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
    Dahele M; Ung YC; Ehrlich L; Silverberg J; Balogh J; Wong CS
    J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer.
    Skoura E; Rondogianni P; Alevizaki M; Tzanela M; Tsagarakis S; Piaditis G; Tolis G; Datseris IE
    Nucl Med Commun; 2010 Jun; 31(6):567-75. PubMed ID: 20335822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.
    Grabellus F; Nagarajah J; Bockisch A; Schmid KW; Sheu SY
    Clin Nucl Med; 2012 Feb; 37(2):121-7. PubMed ID: 22228332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors affecting disease-specific survival in patients with recurrent and/or metastatic differentiated thyroid carcinoma detected by positron emission tomography/computed tomography.
    Akkas BE; Demirel BB; Vural GU
    Thyroid; 2014 Feb; 24(2):287-95. PubMed ID: 23750862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of preoperative 18F-FDG PET/CT in papillary thyroid cancer patients with a high metastatic lymph node ratio: a multicenter retrospective cohort study.
    Kwon SY; Choi EK; Kong EJ; Chong A; Ha JM; Chun KA; Cho IH; Bom HS; Min JJ; Kim J; Song HC; O JH; Kim SH
    Nucl Med Commun; 2017 May; 38(5):402-406. PubMed ID: 28306621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
    Shammas A; Degirmenci B; Mountz JM; McCook BM; Branstetter B; Bencherif B; Joyce JM; Carty SE; Kuffner HA; Avril N
    J Nucl Med; 2007 Feb; 48(2):221-6. PubMed ID: 17268018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
    Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
    Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [
    Nakajo M; Jinguji M; Tani A; Kajiya Y; Nandate T; Kitazano I; Yoshiura T
    Mol Imaging Biol; 2020 Dec; 22(6):1609-1620. PubMed ID: 32651718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.